Rhythm Pharmaceuticals, Inc. reported $240M of revenue over the trailing twelve months, +54% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $240M (to Q2 2026). Net income: −$205M, trailing twelve months to Q2 2026. Operating margin: −85%, trailing twelve months to Q2 2026. EPS: −$3.11, trailing twelve months to Q2 2026.

RYTMRhythm Pharmaceuticals, Inc.

Healthcare

$90.85-5.4% 1Y

$90.85

$75.8252 weeks$117.62

RYTM as reported

Rhythm Pharmaceuticals, Inc. reported $240M of revenue over the trailing twelve months, +54% on the year before. 10 reported series are charted on this page, each one as filed.

$240M

Revenue, trailing twelve months · to Q2 2026 · +54% against the twelve months before

Net income: −$205M
Net income · +12% year on year · trailing twelve months to Q2 2026
Operating margin: −85%
Operating margin · trailing twelve months to Q2 2026
EPS: −$3.11
EPS · +3.3% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RYTM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$240M	+54%	Q2 2026
Net income	−$205M	+12%	Q2 2026
EPS	−$3.11	+3.3%	Q2 2026
Gross margin	89%	n/a	Q2 2026
Operating margin	−85%	n/a	Q2 2026
Net margin	−87%	n/a	Q2 2026
ROE	−159%	n/a	Q2 2026
ROA	−43%	n/a	Q2 2026
ROIC	118%	n/a	Q2 2026
Free cash flow	−$136M	n/a	Q4 2023 · 10 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.